IMUC Key Stats
Street Insider06/02 08:26
PR Newswire06/01 07:30
|06/13/2014||Misc||Annual General Meeting for ImmunoCellular Therapeutics Ltd|
|09/20/2013||Misc||AGM Event for Immunocellular Therapeutics Ltd|
IMUC Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). ImmunoCellular Therapeutics is down 57.50% over the last year vs S&P 500 Total Return up 19.93%, Galena Biopharma up 69.65%, and DelMar Pharmaceuticals down 23.64%.
Balance Sheet View Statement
Y-Ratings for IMUC
Portfolio Strategies Featuring IMUC
Did ImmunoCellular Therapeutics make it into our Portfolio Strategies?
Start your YCharts membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Company Website: http://www.imuc.com
- IR Website: http://investors.imuc.com/
- HQ Country: United States
- HQ State/Province: California
- Incorporation Country: United States
- Incorporation State/Province: Delaware
- Est. Current Fiscal Quarter End: June 30, 2014
- Est. Current Fiscal Year End: December 31, 2014
- Last Fiscal Quarter End: June 30, 2013
- Last Fiscal Year End: December 31, 2013
- NAICS: Research and Development in Biotechnology
- NAICS Code: 541711
- NAICS Industry: Scientific Research and Development Services
- NAICS Sector: Professional, Scientific, and Technical Services
ImmunoCellular Therapeutics Limited is a clinical-stage biotechnology company that develops immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors.
IMUC Excel Add-In Codes
- Name: =YCI("IMUC","name")
- Description: =YCI("IMUC","description")
- Sector: =YCI("IMUC","sector")
- Industry: =YCI("IMUC","industry")
- Est. Current Fiscal Year End: =YCI("IMUC","fye")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.